Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT201 in Advanced Solid Tumors
NCT05729399Phase 2Terminated
- Sponsor
- Grit Biotechnology
- Start
- Sep 2022
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of GT201 in solid tumor, sponsored by Grit Biotechnology. Started Sep 2022; status: terminated.
02
Drugs
GT201
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05729399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05729399.